Abstract: OBJECTIVE To study the protective effect and mechanism of vinpocetine on Parkinson disease cell model. METHODS The Parkinson disease model was established with SH-SY5Y cells injured by 100 μmol·L^-1 6-hydroxydopamine, they were divided into model group and administration groups. Vinpocetine of different concentrations were added to the administration groups and incubated for 24 h on the basis of model group, while vitamin C was added to the blank group under parallel operation. The cell survival rate was detected by CCK-8 kit to define the suitable concentration of vinpocetine. The apoptosis rate and apoptotic morphology were detected by flow cytometry and Hoechst 33258 staining. The content of catalase(CAT), superoxide dismutase(SOD) and malondialdehyde(MDA) were measured by colorimetry. The content of interleukin-1β(IL-1β), interleukin-6(IL-6), tumor necrosis factor-α(TNF-α) were measured by ELISA. Western blotting was used to measure the expression of N-methyl-D-aspartate receptor 1(NMDAR1), α-synuclein and cleaved caspase-9. RESULTS Compared with the model group, with the increase of vinpocetine concentration, the survival rate of cells in the administration groups increased, while the apoptosis rate decreased along with number of apoptotic bodies decreased gradually; the content of CAT and SOD increased while the production of MDA decreased regularly due to the increase of vinpocetine concentration; the content of IL-1β, IL-6 and TNF-α decreased regularly when the vinpocetine concentration enhanced(P<0.05 or P<0.01). The results of Western blotting showed that, compared with model group, the content of NMDAR1 and cleaved caspase-9 in the administration groups was lower while the expression of α-synuclein was increased(P<0.05 or P<0.01). CONCLUSION Vinpocetine can protect the nerve cells of Parkinson disease model by downregulating NMDAR1, upregulating α-synuclein, inhibiting the activation of caspase-9, mitigating the injury of oxidative stress and the production of inflammatory factors.